GILD

Gilead Sciences, Inc. (GILD) | Rumor.io

Gilead Sciences

GILD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#646

Bullish sentiment (50-day avg)91%

Price to earnings ratio17.9

Market capitalization188.7B

Earnings per share-2.66

Dividend yield (TTM)2.16%

Revenue (annual)29.4B

Net income (annual)8.5B

Social

What share of all stock conversation is about GILD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.04	0.01% +0	0.01% +0	0% -0.01

Sep 18

Gilead Sciences' ($GILD) Phase 2 trial for its CDK9 inhibitor, SLS009, has shown better survival and safety data for AML-MR patients, a dire AML prognosis.
The company's secondary asset, SLS009, is already worth 2-3 times its current manipulated market cap, and a Phase 2 AML-MR expansion trial is underway with 80 patients.
Gilead Sciences' ($GILD) acquisition of Magrolimab for $4.9B was based on Phase 1/2 data, which is now being surpassed by SLS009's Phase 2 data for AML-MR patients.

Generated by AI

Sentiment

Of the messages about GILD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	98.04% +14.87	91.19% -2.05	87.44% -0.17
Bearish	—	1.96% -14.87	8.81% +2.05	12.56% +0.17

Bullish· Feb 23

Gilead Sciences' acquisition of Arcellx for $7.8 billion provides a major bullish catalyst, overriding prior bearish guidance and MACD signals.
The acquisition of Arcellx's promising CAR T-cell therapy, anito-cel, for multiple myeloma patients, has significant potential for sales, with projections reaching $6 billion+ by 2029.
The deal is expected to close in Q2 2026, with the company's stock price potentially increasing to $80+ due to the acquisition and its potential for long-term growth.

Bearish· Feb 7

Gilead Sciences' ($GILD) earnings release missed EPS estimates by $0.04, despite revenue beating expectations.
The company's Trodelvy will face increased pressure after a competitor's (AstraZeneca's) treatment showed better results in clinical trials.
Gilead Sciences' ($GILD) fourth quarter was "mildly disappointing" due to missing expectations for Biktarvy and Descovy, as well as light profit and guidance.

Generated by AI

Topics

Of the messages about GILD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	86.96%	66.38%	20.44%
Technical Analysis	0%	13.04%	7.82%	6.12%
Analysts	0%	0%	10.36%	25.95%
Macro	0%	0%	15.43%	45.61%
Controversies	0%	0%	0%	0.29%
Earnings	0%	0%	0%	1.58%

Earnings· Aug 4

Gilead Sciences reported Q2 2026 earnings with revenue of $7.8B, beating estimates by $400M, and non-GAAP EPS of -$6.75, beating estimates by $0.50.
The company's core business continued to gain momentum, with product sales excluding Veklury increasing 10% year-over-year to $7.6B, and Biktarvy sales rising 7% year-over-year to $3.8B.
Gilead narrowed its FY 2026 product sales guidance to $30.1B-$30.4B, and reduced its non-GAAP diluted loss per share guidance to between $(0.65) and $(0.30).

Analysts· Oct 31

Barclays upgraded Gilead Sciences to Equal Weight and raised the price target from $60 to $76.
Multiple analysts, including Carter Gould and Brian Abrahams, raised their price targets for Gilead Sciences, with targets ranging from $75 to $92.
Analysts attributed the price target increases to Gilead's strong Q3 results, driven by its Veklury and HIV franchise.

Announcements· Aug 4

Gilead Sciences reported Q2 2026 earnings with revenue of $7.8B, a 10% YoY increase, and adjusted loss/share of $6.75, beating estimates.
The company's base business, excluding Veklury, saw a 10% YoY increase in revenue to $7.6B, with HIV sales rising 12% to $5.7B.
Gilead raised its full-year HIV growth guidance to 8-10% YoY, with launch preparations underway for Anito-cel cell therapy.

Controversies· Oct 23

The FDA has approved Gilead Sciences' ($GILD) remdesivir as a treatment for COVID-19, with the drug's approval coming after a contentious debate between Donald Trump and Joe Biden.
The approval of remdesivir has led to a significant increase in trading volume for Gilead Sciences, with over 30 million shares changing hands.
Gilead Sciences' remdesivir has been authorized for emergency use in the past, but this is the first time it has been approved as a treatment for COVID-19, with some questioning the FDA's decision-making process.

Macro· Jun 8

Gilead Sciences, Inc. ($GILD) stock may be a good buy at $73 due to its "miracle" drug.
The company's stock performance is expected to be influenced by its ability to deliver successful treatments.
Investors should consider Gilead's prospects in the pharmaceutical industry when making investment decisions.

Technical Analysis· Jan 7

$GILD has formed a giant mountain followed by a tail, indicating a long-term trend reversal.
The stock is above its 50-day moving average for the first time since July and is nearing the top of its Bollinger Bands.
A double bottom pattern has formed, with a weekly MACD cross and a bullish engulfing candle, and the price is approaching potential resistance at $64.

Generated by AI

Community

Of the messages about GILD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	40.86%	45.13%	58.12%
Newcomers	12.5%	59.14%	54.87%	41.88%

Regulars· Aug 5

Gilead Sciences' HIV prevention franchise has crossed $1B in quarterly sales for the first time, a significant milestone for the company.
Despite beating expectations, Gilead's shares are experiencing continued worries over the long-term outlook, with some investors looking to diversify the company's pipeline beyond virology.
Gilead's second-quarter earnings were impacted by increased research and development costs, but the company's HIV drug sales helped lift revenue, with HIV remaining the strongest franchise in the quarter.

Newcomers· Sep 17

The newcomer is focused on understanding the commodity price environment and margin stability for Micron and SKhynix shares, and how it affects their shares.
The newcomer is considering a conservative approach by investing in dividend stocks like Takeda or Gilead, and questioning the viability of leveraging stocks.
The newcomer is exploring Gilead Sciences' stock performance and intrinsic value through analysis of financial data, valuation models, and market intelligence.

Generated by AI

BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.

22h agoYahoo Finance

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]

1d agoYahoo Finance

Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?

At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]

1d agoYahoo Finance

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

1d agoYahoo Finance

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

1d agoYahoo Finance

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?

Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...

1d agoYahoo Finance

Also Discussed

Investors talking about GILD also mention

#	Name	Attention
1	Biogen IncBIIB	0%-0.01
2	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
3	AbbVie Inc.ABBV	0.03%-0.03
4	Galapagos NV American Depositary ReceiptGLPG	0%0
5	Amgen Inc.AMGN	0.01%+0
6	iShares Biotechnology ETFIBB	0.01%0
7	Bristol-Myers Squibb CompanyBMY	0.01%0
8	Novartis AG Sponsored ADRNVS	0%-0.01
9	GSK plc ADRGSK	0%0
10	Merck & Co., Inc.MRK	0.01%-0.06

Gilead Sciences, Inc.

Healthcare
Drug Manufacturers - General

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs. Gilead Sciences specializes in therapeutic areas including HIV, viral hepatitis, oncology, inflammation, respiratory conditions, and cardiovascular disease. Its current portfolio includes prescription medicines and specialty treatments used in hospitals, clinics, and long-term care settings, supporting patients across global markets. The company also maintains an active pipeline in virology, oncology, and inflammation, reinforcing its role as a major provider of branded therapies in modern healthcare. Headquartered in Foster City, California, Gilead Sciences serves physicians, healthcare systems, and patients through a diversified product portfolio centered on infectious disease and specialty care.

Website

Location

333 Lakeside Drive

Foster City, CA, 94404

United States

Social

What share of all stock conversation is about GILD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.04	0.01% +0	0.01% +0	0% -0.01

Sep 18

Gilead Sciences' ($GILD) Phase 2 trial for its CDK9 inhibitor, SLS009, has shown better survival and safety data for AML-MR patients, a dire AML prognosis.
The company's secondary asset, SLS009, is already worth 2-3 times its current manipulated market cap, and a Phase 2 AML-MR expansion trial is underway with 80 patients.
Gilead Sciences' ($GILD) acquisition of Magrolimab for $4.9B was based on Phase 1/2 data, which is now being surpassed by SLS009's Phase 2 data for AML-MR patients.

Generated by AI

Sentiment

Of the messages about GILD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	98.04% +14.87	91.19% -2.05	87.44% -0.17
Bearish	—	1.96% -14.87	8.81% +2.05	12.56% +0.17

Bullish· Feb 23

Gilead Sciences' acquisition of Arcellx for $7.8 billion provides a major bullish catalyst, overriding prior bearish guidance and MACD signals.
The acquisition of Arcellx's promising CAR T-cell therapy, anito-cel, for multiple myeloma patients, has significant potential for sales, with projections reaching $6 billion+ by 2029.
The deal is expected to close in Q2 2026, with the company's stock price potentially increasing to $80+ due to the acquisition and its potential for long-term growth.

Bearish· Feb 7

Gilead Sciences' ($GILD) earnings release missed EPS estimates by $0.04, despite revenue beating expectations.
The company's Trodelvy will face increased pressure after a competitor's (AstraZeneca's) treatment showed better results in clinical trials.
Gilead Sciences' ($GILD) fourth quarter was "mildly disappointing" due to missing expectations for Biktarvy and Descovy, as well as light profit and guidance.

Generated by AI

Topics

Of the messages about GILD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	86.96%	66.38%	20.44%
Technical Analysis	0%	13.04%	7.82%	6.12%
Analysts	0%	0%	10.36%	25.95%
Macro	0%	0%	15.43%	45.61%
Controversies	0%	0%	0%	0.29%
Earnings	0%	0%	0%	1.58%

Earnings· Aug 4

Gilead Sciences reported Q2 2026 earnings with revenue of $7.8B, beating estimates by $400M, and non-GAAP EPS of -$6.75, beating estimates by $0.50.
The company's core business continued to gain momentum, with product sales excluding Veklury increasing 10% year-over-year to $7.6B, and Biktarvy sales rising 7% year-over-year to $3.8B.
Gilead narrowed its FY 2026 product sales guidance to $30.1B-$30.4B, and reduced its non-GAAP diluted loss per share guidance to between $(0.65) and $(0.30).

Analysts· Oct 31

Barclays upgraded Gilead Sciences to Equal Weight and raised the price target from $60 to $76.
Multiple analysts, including Carter Gould and Brian Abrahams, raised their price targets for Gilead Sciences, with targets ranging from $75 to $92.
Analysts attributed the price target increases to Gilead's strong Q3 results, driven by its Veklury and HIV franchise.

Announcements· Aug 4

Gilead Sciences reported Q2 2026 earnings with revenue of $7.8B, a 10% YoY increase, and adjusted loss/share of $6.75, beating estimates.
The company's base business, excluding Veklury, saw a 10% YoY increase in revenue to $7.6B, with HIV sales rising 12% to $5.7B.
Gilead raised its full-year HIV growth guidance to 8-10% YoY, with launch preparations underway for Anito-cel cell therapy.

Controversies· Oct 23

The FDA has approved Gilead Sciences' ($GILD) remdesivir as a treatment for COVID-19, with the drug's approval coming after a contentious debate between Donald Trump and Joe Biden.
The approval of remdesivir has led to a significant increase in trading volume for Gilead Sciences, with over 30 million shares changing hands.
Gilead Sciences' remdesivir has been authorized for emergency use in the past, but this is the first time it has been approved as a treatment for COVID-19, with some questioning the FDA's decision-making process.

Macro· Jun 8

Gilead Sciences, Inc. ($GILD) stock may be a good buy at $73 due to its "miracle" drug.
The company's stock performance is expected to be influenced by its ability to deliver successful treatments.
Investors should consider Gilead's prospects in the pharmaceutical industry when making investment decisions.

Technical Analysis· Jan 7

$GILD has formed a giant mountain followed by a tail, indicating a long-term trend reversal.
The stock is above its 50-day moving average for the first time since July and is nearing the top of its Bollinger Bands.
A double bottom pattern has formed, with a weekly MACD cross and a bullish engulfing candle, and the price is approaching potential resistance at $64.

Generated by AI

Community

Of the messages about GILD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	40.86%	45.13%	58.12%
Newcomers	12.5%	59.14%	54.87%	41.88%

Regulars· Aug 5

Gilead Sciences' HIV prevention franchise has crossed $1B in quarterly sales for the first time, a significant milestone for the company.
Despite beating expectations, Gilead's shares are experiencing continued worries over the long-term outlook, with some investors looking to diversify the company's pipeline beyond virology.
Gilead's second-quarter earnings were impacted by increased research and development costs, but the company's HIV drug sales helped lift revenue, with HIV remaining the strongest franchise in the quarter.

Newcomers· Sep 17

The newcomer is focused on understanding the commodity price environment and margin stability for Micron and SKhynix shares, and how it affects their shares.
The newcomer is considering a conservative approach by investing in dividend stocks like Takeda or Gilead, and questioning the viability of leveraging stocks.
The newcomer is exploring Gilead Sciences' stock performance and intrinsic value through analysis of financial data, valuation models, and market intelligence.

Generated by AI

Gilead Sciences

Social

Sep 18

Bullish· Feb 23

Bearish· Feb 7

Earnings· Aug 4

Analysts· Oct 31

Announcements· Aug 4

Controversies· Oct 23

Macro· Jun 8

Technical Analysis· Jan 7

Regulars· Aug 5

Newcomers· Sep 17

Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?

Also Discussed

Gilead Sciences, Inc.

Company Information

Location

Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?

Also Discussed

Social

Sep 18

Bullish· Feb 23

Bearish· Feb 7

Earnings· Aug 4

Analysts· Oct 31

Announcements· Aug 4

Controversies· Oct 23

Macro· Jun 8

Technical Analysis· Jan 7

Regulars· Aug 5

Newcomers· Sep 17